KTTA
Pasithea Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · US
$0.58
−0.05%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 27.69x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.39x
- Price / sales
- —
- Price / cash flow
- -1.09x
Enterprise value
- Enterprise value
- -$45.6B
- EV / sales
- —
- EV / EBITDA
- 1958.82x
- EV / EBIT
- 1905.33x
- Market cap
- $19.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026